Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition

Overview of attention for article published in Frontiers in immunology, April 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter: 1 X user

patent: 1 patent

Citations

dimensions_citation: 40 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

METHOD AND MEDICAMENT FOR TREATING CANCER UNRESPONSIVE TO PD-1/PD-L1 SIGNALING INHIBITOR

Application EP-3873527-A4

European Patent Office

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.